A biotech catalyst watch list is a dated list of events that can revalue a company in a single session. Building one is straightforward. Keeping it honest, so that it reflects what is actually knowable today rather than what turned out to be true later, is the part most watch lists get wrong.
Biotech Stock Catalysts and PDUFA Dates: The Pharma Watch List for Investors
The catalyst types worth tracking
Regulatory decisions. PDUFA dates on new drug and biologics applications, and on supplemental filings for label expansions. These are the only catalysts with a date the regulator has committed to, which is what makes them the backbone of a watch list.
Advisory committee meetings. Scheduled before the decision, with a published briefing document and a public vote. The vote is non-binding but frequently moves a stock more than the approval that follows.
Late-stage data readouts. Phase 3 topline results, and Phase 2 results for a lead asset in a small company. These usually carry guidance to a quarter or a half rather than a day, so they belong on a watch list as a window.
Financing and runway events. A company with under twelve months of cash has a dilution catalyst whether or not it has announced one, and that shapes how any clinical result gets priced.
How to size a catalyst before it happens
Three questions do most of the work. How much of the company is this asset, measured against cash and against the rest of the pipeline? What is the realistic base rate for this event, given the phase, the indication and whether the endpoint has been hit before? And what is already priced in, judged by the run-up into the date rather than by the headline market cap?
The third question is where watch lists most often fail. A well-telegraphed approval that a stock has already rallied fifty percent into can fall on the good news, and nothing in the calendar entry itself tells you that.
Reading a Phase 3 readout properly
"Met the primary endpoint" is the headline, and on its own it settles less than it appears to. Three things decide what the result is worth.
The effect size against the comparator. A statistically significant result on a small absolute difference can still fail commercially, because payers and prescribers compare against whatever is already on the market rather than against placebo.
Whether the comparator was the standard of care. A trial run against placebo in a disease that already has effective treatment answers a regulatory question, not a commercial one.
The safety picture at the dose that worked. Efficacy and tolerability often peak at different doses, and a discontinuation rate buried in the secondary data can matter more to the launch than the primary endpoint did.
A missed primary endpoint is not automatically fatal either. Trials miss on enrolment, on a comparator that outperformed, or on an endpoint that was too ambitious, and a company with cash can redesign and run again. What matters is whether the mechanism still looks alive.
Common ways a watch list goes wrong
Treating a date as an appointment. Regulators act early, trials report late, and companies announce when it suits them. Every entry should be a window.
Counting one event twice. A drug with two applications, or a partner and an originator announcing the same decision, can appear as two catalysts and inflate what looks like a busy month.
Dropping the losers. Removing failed catalysts from the record makes the list look far more predictive than it was. Keep the misses, with their outcomes, or the list cannot teach you anything.
Ignoring the balance sheet. A good result at a company with six months of cash is a financing announcement waiting to happen, and the dilution frequently arrives within days of the good news.
Keeping the list honest
Dates move. Companies extend guidance, the FDA issues extensions, and trials read out late. A watch list that silently overwrites the old date loses the most useful record it had, which is what was expected and when it changed. Keep the revision, not just the current value.
Outcomes also need to be recorded against the date they resolved, not against the date they were expected. A decision that arrived early, as several do each year, otherwise looks like a date that passed with no news.
Where to get the dates
Our FDA calendar carries upcoming decisions and dated clinical events across the listed biotech universe, with the drug, indication and sponsor attached. The PDUFA calendar covers regulatory decision dates on their own, and the historical record keeps resolved decisions with their outcomes so a past date can still be audited.
For a company-level view, each profile carries that company's dated catalysts alongside its cash position and runway, which is the context that turns a date into a position size.
Frequently asked questions
What is a biotech catalyst?
A biotech catalyst is a dated event that can materially revalue a company, most often an FDA decision, an advisory committee meeting, a clinical trial readout, or a financing event. The defining feature is that the market knows roughly when it is coming.
Which catalysts move biotech stocks the most?
Phase 3 topline results and FDA decisions on a company's lead asset move small and mid-cap biotech hardest, because the asset represents most of the company's value. Advisory committee votes often produce larger moves than the approval that follows, since the vote resolves most of the uncertainty.
How do I know if a catalyst is already priced in?
Look at the run-up into the date rather than the absolute valuation. A stock that has rallied substantially in the weeks before a decision has already priced much of a positive outcome, which is why approvals sometimes sell off.
How far ahead are PDUFA dates known?
Usually six to ten months. The clock starts when the FDA accepts the filing, and the company normally announces both the acceptance and the goal date at that point, so the date enters the calendar well before the decision.
What should I do when a catalyst date passes with no news?
Check for an extension first, since a major amendment can push a goal date out by about three months. Then check the company's own newsroom, because a decision is often announced there before it appears in any regulatory filing.